Toll-like receptor 4 gene polymorphism influences dendritic cell in vitro function and clinical outcomes in vaccinated melanoma patients

Human TLRs and IL-1Rs in Host Defense: Natural Insights from Evolutionary, Epidemiological, and Clinical Genetics

(2011) Jean-Laurent Casanova et al.   Annual Review of Immunology

Enhanced Efficacy of Therapeutic Cancer Vaccines Produced by Co-Treatment with Mycobacterium tuberculosis Heparin-Binding Hemagglutinin, a Novel TLR4 Agonist

(2011) I. D. Jung et al.   CANCER RESEARCH

Heat-Shock Induction of Tumor-Derived Danger Signals Mediates Rapid Monocyte Differentiation into Clinically Effective Dendritic Cells

(2011) R. Aguilera et al.   CLINICAL CANCER RESEARCH

Third generation dendritic cell vaccines for tumor immunotherapy

(2011) Bernhard Frankenberger et al.   EUROPEAN JOURNAL OF CELL BIOLOGY

CD83 increases MHC II and CD86 on dendritic cells by opposing IL-10–driven MARCH1-mediated ubiquitination and degradation

(2011) Lina E. Tze et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Toll-like receptor 4 single-nucleotide polymorphisms Asp299Gly and Thr399Ile in head and neck squamous cell carcinomas

(2011) Christoph Bergmann et al.   Journal of Translational Medicine

Association of Inherited Variation in Toll-Like Receptor Genes with Malignant Melanoma Susceptibility and Survival

(2011) Andreas Gast et al.   PLoS One

Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy

(2010) Gerty Schreibelt et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Impact of Toll-like receptor 4 polymorphisms on risk of cancer

(2010) Anton G. Kutikhin   HUMAN IMMUNOLOGY

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

Toll-like receptor agonists in cancer therapy

(2009) Sylvia Adams   Immunotherapy

Prolonged Survival of Dendritic Cell–Vaccinated Melanoma Patients Correlates With Tumor-Specific Delayed Type IV Hypersensitivity Response and Reduction of Tumor Growth Factor β-Expressing T Cells

(2009) Mercedes N. López et al.   JOURNAL OF CLINICAL ONCOLOGY

Peroxiredoxin 1 Stimulates Secretion of Proinflammatory Cytokines by Binding to TLR4

(2009) J. R. Riddell et al.   JOURNAL OF IMMUNOLOGY

Immunogenic death of colon cancer cells treated with oxaliplatin

(2009) A Tesniere et al.   ONCOGENE

Anti- and proinflammatory cytokine gene polymorphism and genetic predisposition: association with smoking, tumor stage and grade, and bacillus Calmette-Guérin immunotherapy in bladder cancer

(2008) Dinesh Ahirwar et al.   CANCER GENETICS AND CYTOGENETICS

Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy

(2008) Constantin N. Baxevanis et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes

(2008) D. Santini et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Cancer vaccines for established cancer: how to make them better?

(2008) Daniel M. Andrews et al.   IMMUNOLOGICAL REVIEWS